Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation

This article was originally published in The Pink Sheet Daily


Related Content

Lilly Brings Non-Inferiority Data To GLP-1 Show Down
Lilly Gets Ready To Compete With Its Late-Stage Diabetes Pipeline
Lilly Discusses GLP-1 Strategy At ADA, Readies For Dulaglutide Filing
In A Changing Diabetes Drug Market, Who Will Come Out On Top?
With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn
AstraZeneca, BMY To Target Disease Management And Primary Care Synergies With Amylin Acquisition
Amylin's Once-Weekly Bydureon Clears Major Cardiac Safety Hurdle
Lilly Sales Reps Resume Launch Of BI's Tradjenta; Judge Says FDA Regs Protect Byetta
Caught Between Two Partners: Amylin Seeks To Block Lilly's Byetta Sales Force From Marketing Tradjenta
Roche/Ipsen's Suspended Taspoglutide Could Become Another Diabetes Casualty


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts